Antibody Targeting to a Class I MHC-Peptide Epitope Promotes Tumor Cell Death

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Journal of Immunology

• Publication date

  2006-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.177.6.4187PMID 16951384
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Human natural killer cell development and biology.

  2006cited by this paper
• The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells.

  2005cited by this paper
• Immunogenic HER-2/neu peptides as tumor vaccines

  2005cited by this paper
• Breaking down the barriers to cancer immunotherapy

  2005cited by this paper
• Assessment of CD8 involvement in T cell clone avidity by direct measurement of HLA‐A2/Mage3 complex density using a high‐affinity TCR like monoclonal antibody

  2005cited by this paper
• HLA class I and II genotype of the NCI-60 cell lines

  2005cited by this paper
• Antitumor Activity of Orally Bioavailable Farnesyltransferase Inhibitor, ABT-100, Is Mediated by Antiproliferative, Proapoptotic, and Antiangiogenic Effects in Xenograft Models

  2005cited by this paper
• A listing of human tumor antigens recognized by T cells: March 2004 update

  2005cited by this paper
• ‘‘Homologous restriction’’ in complement lysis: roles of membrane complement regulators

  2005cited by this paper
• Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines

  2005cited by this paper
• A Novel Human Cancer Vaccine Elicits Cellular Responses to the Tumor-Associated Antigen, Human Chorionic Gonadotropin β

  2004cited by this paper
• Dissecting cytotoxic T cell responses towards the NY‐ESO‐1 protein by peptide/MHC‐specific antibody fragments

  2004influential reference
• A Comparison of the in Vitro and in Vivo Activities of IgG and F(ab′)2 Fragments of a Mixture of Three Monoclonal Anti-Her-2 Antibodies

  2004cited by this paper
• Cutting Edge: Heterozygote Advantage in Autoimmune Disease: Hierarchy of Protection/Susceptibility Conferred by HLA and Killer Ig-Like Receptor Combinations in Psoriatic Arthritis1

  2004cited by this paper
• Antilymphoma Effects of Anti-HLA-DR and CD20 Monoclonal Antibodies (Lym-1 and Rituximab) on Human Lymphoma Cells

  2004cited by this paper
• Post-proteasomal antigen processing for major histocompatibility complex class I presentation

  2004cited by this paper
• The major hormone-specific discontinuous epitopes on human chorionic gonadotrophin.

  2004cited by this paper
• Human chorionic gonadotropin in cancer.

  2004cited by this paper
• Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1

  2003cited by this paper
• Selective Targeting of Melanoma and APCs Using a Recombinant Antibody with TCR-Like Specificity Directed Toward a Melanoma Differentiation Antigen 1

  2003cited by this paper
• Immunotherapy: past, present and future

  2003cited by this paper
• Genetic engineering of T cell specificity for immunotherapy of cancer.

  2003cited by this paper
• Recombinant antibodies with MHC‐restricted, peptide‐specific, T‐cell receptor‐like specificity: new tools to study antigen presentation and TCR–peptide–MHC interactions

  2003influential reference
• Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

  2002cited by this paper
• TCR-Like Human Antibodies Expressed on Human CTLs Mediate Antibody Affinity-Dependent Cytolytic Activity1

  2002cited by this paper
• Cytokine enhancement of in vitro antibody-dependent cellular cytotoxicity mediated by chimeric anti-GD3 monoclonal antibody KM871.

  2002cited by this paper
• Tumor-associated antigen human chorionic gonadotropin beta contains numerous antigenic determinants recognized by in vitro-induced CD8+ and CD4+ T lymphocytes

  2002cited by this paper
• Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.

  2001cited by this paper
• A listing of human tumor antigens recognized by T cells

  2001cited by this paper
• Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies

  2001cited by this paper
• Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library.

  2000influential reference
• The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation

  2000cited by this paper
• Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Human and rodent decay‐accelerating factors (CD55) are not species restricted in their complement‐inhibiting activities

  2000cited by this paper
• Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms

  2000cited by this paper
• CD94/NKG2-A inhibitory complex blocks CD16-triggered Syk and extracellular regulated kinase activation, leading to cytotoxic function of human NK cells.

  1999cited by this paper
• Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition.

  1998cited by this paper
• Fc receptors are required in passive and active immunity to melanoma.

  1998cited by this paper
• Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59.

  1997cited by this paper
• Peptide-specific killing of antigen-presenting cells by a recombinant antibody-toxin fusion protein targeted to major histocompatibility complex/peptide class I complexes with T cell receptor-like specificity.

  1997cited by this paper
• Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody.

  1997cited by this paper
• Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.

  1996cited by this paper
• Phenotypic Analysis of Antigen-Specific T Lymphocytes

  1996cited by this paper
• A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells.

  1996cited by this paper
• HLA-A2 molecules in an antigen-processing mutant cell contain signal sequence-derived peptides

  1992cited by this paper
• Immunomodulation of experimental allergic encephalomyelitis by antibodies to the antigen–Ia complex

  1991cited by this paper
• Homologous species restriction of the complement-mediated killing of nucleated cells.

  1990cited by this paper
• Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo.

  1988cited by this paper
• Segmental flexibility and complement fixation of genetically engineered chimeric human, rabbit and mouse antibodies.

  1988cited by this paper
• Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants.

  1986cited by this paper
• Mechanism of antitumor activity in mice for anti-epidermal growth factor receptor monoclonal antibodies with different isotypes.

  1986cited by this paper
• Importance of immunoglobulin isotype in human antibody-dependent, cell- mediated cytotoxicity directed by murine monoclonal antibodies

  1985cited by this paper
• Influence of antibody isotype on passive serotherapy of lymphoma.

  1985cited by this paper
• Journal of Immune Based Therapies and Vaccines Tumor–associated Antigens Identified by Mrna Expression Profiling as Tumor Rejection Epitopes Tumor Associated Antigensmrna Microassaypeptide P53vaccination

  year unknowncited by this paper

• T cell receptor-like antibody specifically targets and eliminates cells infected with cytomegalovirus

  2025cites this paper
• Immunotherapy targeting a leader sequence cathepsin G-derived peptide

  2025cites this paper
• Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager

  2025cites this paper
• CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo.

  2025cites this paper
• Development of an innovative approach for early diagnosis of cervical cancer using TCR-like antibodies targeting HPV18 E6 and E7 peptides

  2025cites this paper
• A modified SELEX approach to identify DNA aptamers with binding specificity to the major histocompatibility complex presenting ovalbumin model antigen

  2023cites this paper
• Facile repurposing of peptide–MHC-restricted antibodies for cancer immunotherapy

  2023cites this paper
• Self-Induced Back-Action Actuated Nanopore Electrophoresis (SANE) Sensor for Label-Free Detection of Cancer Immunotherapy-Relevant Antibody-Ligand Interactions.

  2022cites this paper
• Identification of Neoantigens in Cancer Cells as Targets for Immunotherapy

  2022cites this paper
• Evaluation of chimeric antigen receptor of humanized rabbit‐derived T cell receptor‐like antibody

  2022cites this paper
• Rapid and efficient generation of T‐cell receptor‐like antibodies using chip‐based single‐cell analysis

  2021cites this paper
• TARP as antigen in cancer immunotherapy

  2021cites this paper
• The potential applications of T cell receptor (TCR)-like antibody in cervical cancer immunotherapy

  2021cites this paper
• T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy

  2021cites this paper
• Selection of a Single Domain Antibody, Specific for an HLA-Bound Epitope of the Mycobacterial Ag85B Antigen

  2020cites this paper
• Transcriptomic Analysis of Breast Cancer Patients Sensitive and Resistant to Chemotherapy: Looking for Overall Survival and Drug Resistance Biomarkers

  2020cites this paper
• Utilising molecular dynamics simulations to understand and engineer T-cell receptors

  2020cites this paper
• Targeting the MHC Ligandome by Use of TCR-Like Antibodies

  2019cites this paper
• Opportunities and Challenges for Antibodies against Intracellular Antigens

  2019cites this paper
• High throughput development of TCR-mimic antibody that targets survivin-2B80-88/HLA-A*A24 and its application in a bispecific T-cell engager

  2019cites this paper
• T cell receptor‐based cancer immunotherapy: Emerging efficacy and pathways of resistance

  2019cites this paper
• Detection of specific antibody-ligand interactions with a self-induced back-action actuated nanopore electrophoresis sensor

  2019cites this paper
• TCR-like antibodies in cancer immunotherapy

  2019cites this paper
• T-cell receptor mimic (TCRm) antibody therapeutics against intracellular proteins

  2019cites this paper
• T Cell Receptor Mimic Antibodies

  2018cites this paper
• T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases

  2017cites this paper
• Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.

  2017influential citation
• Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies

  2017cites this paper
• Therapeutic Antibodies against Intracellular Tumor Antigens

  2017influential citation
• In-silico discovery of cancer-specific peptide-HLA complexes for targeted therapy

  2016cites this paper
• Targeting Epstein-Barr virus-transformed B lymphoblastoid cells using antibodies with T-cell receptor-like specificities.

  2016cites this paper
• Opportunities and challenges for TCR mimic antibodies in cancer therapy

  2016cites this paper
• T cell receptor mimic antibodies for cancer therapy

  2016cites this paper
• TherapeuticEfficacyofanFc-EnhancedTCR-likeAntibodyto the Intracellular WT1 Oncoprotein

  2014cites this paper
• Cancer Therapy: Preclinical TherapeuticEfficacyof anFc-EnhancedTCR-likeAntibody to the Intracellular WT1 Oncoprotein

  2014cites this paper
• TCR-MHC/peptide interaction: prospects for new anti-tumoral agents.

  2014cites this paper
• Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein

  2014cites this paper
• Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.

  2013cites this paper
• T-Cell Receptor-Like Antibodies: Targeting the Intracellular Proteome Therapeutic Potential and Clinical Applications

  2013cites this paper
• Antigen-specific immunomodulation for type 1 diabetes by novel recombinant antibodies directed against diabetes-associates auto-reactive T cell epitope.

  2013cites this paper
• Personalized Peptide Vaccine as a Novel Immunotherapy Against Advanced Cancer

  2013cites this paper
• T-cell-receptor-like antibodies – generation, function and applications

  2012cites this paper
• Potential antitumor applications of a monoclonal antibody specifically targeting human papilloma virus 16 E749–57 peptide

  2012cites this paper
• Optimisation of T cell receptor antigen recognition for targeting disease

  2011cites this paper
• An anti-PR1/HLA-A2 T-cell receptor-like antibody mediates complement-dependent cytotoxicity against acute myeloid leukemia progenitor cells.

  2011cites this paper
• Antibodies to peptide–HLA complexes have potential application for cancer diagnosis and therapy

  2011cites this paper
• Effector-Independent Mechanisms Apoptosis of Tumor Cells via Immune TCR Mimic Monoclonal Antibodies Induce

  2011cites this paper
• TCR Mimic Monoclonal Antibodies Induce Apoptosis of Tumor Cells via Immune Effector-Independent Mechanisms

  2011cites this paper
• Expanding the Targets Available to Therapeutic Antibodies via Novel Disease-specific Markers

  2011cites this paper
• Retargeting NK92 cells using an HLA-A2-restricted, EBNA3C-specific chimeric antigen receptor

  2011cites this paper
• Direct discovery and validation of a peptide/MHC epitope expressed in primary human breast cancer cells using a TCRm monoclonal antibody with profound antitumor properties

  2010cites this paper
• Using Breast Cancer Models Significantly Impedes Tumor Growth In Vivo Specific Peptide/HLA Class I Complex and TCR Mimic Monoclonal Antibody Targets a

  2010cites this paper
• TCR Mimic Monoclonal Antibody Targets a Specific Peptide/HLA Class I Complex and Significantly Impedes Tumor Growth In Vivo Using Breast Cancer Models

  2010cites this paper
• HLA class I molecules reflect an altered host proteome after influenza virus infection.

  2010cites this paper
• Can oligomeric T-cell receptor be used as a tool to detect viral peptide epitopes on infected cells?

  2009cites this paper
• HLA-omics and cancer biomarkers: emerging tools and technologies for the medical laboratory.

  2008cites this paper
• Identification of breast cancer peptide epitopes presented by HLA-A*0201.

  2008cites this paper
• Assessing vaccine potency using TCRmimic antibodies.

  2008cites this paper
• Direct class I HLA antigen discovery to distinguish virus-infected and cancerous cells

  2006cites this paper
• Nucleusnewsletter of the School of Pharmacy's Office of Research

  2006cites this paper